المؤلفون: Hozefa A. Divan, Marisa A. Bittoni, Ashok Krishna, David P. Carbone

المصدر: BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)

مصطلحات موضوعية: Non-small cell lung cancer, PD-1 inhibitors, PD-L1 inhibitors, Real-world evidence, Patient characteristics, Observational study, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background Patients from non-small cell lung cancer (NSCLC) controlled clinical trials do not always reflect real-world heterogeneous patient populations. We designed a study to describe the real-world patient characteristics and treatment patterns of first-line treatment in patients in the US with NSCLC. Methods This was an observational, retrospective cohort study based on electronic medical records of US adults with locally advanced or metastatic disease in the ConcertAI Patient360 NSCLC database who initiated first-line treatment with anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) therapy between July 2016 and December 2020. The analysis used patient attributes, clinical characteristics, and treatments from each patient’s medical records. Results A total of 2175 patients were eligible for analysis. The median age was 68 years, and 26.2% of the patients were ≥75 years old. At treatment initiation, 96.4% and 3.6% of the patients had Stage 4 and Stage 3 (B or C) NSCLC, respectively. The most common histology type was nonsquamous adenocarcinoma (66.4%), and 19.8% had Eastern Cooperative Oncology Group performance status ≥2. Immunosuppressive medications were being used by 17.7% of patients, and 11.0% were immunocompromised. Almost all patients had metastases: 64.6% had 1, 23.2% had 2, and 8.0% had ≥3 metastatic sites. Brain metastases were present in 22.9% of patients. Treatment evolution was observed with first-line standard of care shifting from single-agent immunotherapy in 2016 (90.2%) to combination immunotherapy and chemotherapy in 2020 (60.2%). Conclusion Between 2016 and 2020, the first-line treatment paradigm for advanced NSCLC in the US shifted from anti–PD-1/PD-L1 monotherapy to combination chemoimmunotherapy, with increasing biomarker testing. Further research in heterogeneous patient populations to characterize treatment strategies is warranted.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/aa594b592c1d4e0e9a2a1f1be367ad4aTest

المؤلفون: Bittoni, Cecilia

الوصف: On April 11th, 2024, four events merged into this 2024 Ocean Decade Conference Satellite Event hosted by DCC-CR and co-hosted by CoastPredict Programme, Knowledge Hub on Sea Level Rise and Ocean and Climate Platform . This report summarises the results on engaging participants through polls and Q&A sessions to gather insights on coastal resilience, sea-level rise impacts, and international milestones for advancing resilience. Key outcomes included high engagement levels, with 110 out of 124 participants actively involved, and significant participation in polls. The event highlighted strategies for supporting coastal resilience, diverse interpretations of coastal resilience, and relevant sea-level rise-induced impacts. Additionally, anticipated international milestones and contributions to strengthening multi-hazard warning systems were discussed. The outcomes of the event align closely with the objectives of the Ocean Decade and Vision 2030 white paper 6, emphasising the importance of collaboration, ...

العلاقة: https://dx.doi.org/10.5281/zenodo.11198778Test

الإتاحة: https://doi.org/10.5281/zenodo.1119877910.5281/zenodo.11198778Test

المؤلفون: Spakowicz, D., Bibi, A., Jahanbakhshi, S., Williams, N., Hoyd, R., Pallerla, A., Wheeler, C., Bittoni, M., Zhang, S., Amann, J., Suman, S., Webb, M., Grainger, E., Heitman, K., Grogan, M., Presley, C., Vodovotz, Y., Zhu, J., Clinton, S., Carbone, D.P.

المصدر: ESMO Open ; volume 9, page 102651 ; ISSN 2059-7029

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.esmoop.2024.102651Test
https://api.elsevier.com/content/article/PII:S2059702924004198?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2059702924004198?httpAccept=text/plainTest

المؤلفون: Alessandro Passardi, Irene Azzali, Alessandro Bittoni, Giorgia Marisi, Francesca Rebuzzi, Chiara Molinari, Giulia Bartolini, Laura Matteucci, Francesco Giulio Sullo, Silvia Angela Debonis, Chiara Gallio, Manlio Monti, Martina Valgiusti, Margherita Muratore, Ilario Giovanni Rapposelli, Paola Ulivi, Giovanni Luca Frassineti

المصدر: Therapeutic Advances in Medical Oncology, Vol 15 (2023)

مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Background: Validated predictors of sensitivity or resistance to Bevacizumab (Bev) are not available, and Inflammatory Indexes (IIs) has been reported to be useful prognostic factors in various malignant solid tumours, including metastatic colorectal cancer (mCRC). Objectives: To explore the prognostic value of IIs in mCRC patients treated with first-line chemotherapy plus Bev. Design: One hundred and eighty-two patients diagnosed with mCRC and treated with first line chemotherapy plus Bev were considered for this prospective non-pharmacological study. Neutrophil, lymphocyte, platelet, aspartate transaminase (AST) and lactate dehydrogenase (LDH) tests were carried out at baseline and before each treatment cycle, according to clinical practice. Methods: Pre-treatment Systemic Immune-inflammation Index (SII), Colon Inflammatory Index (CII) and Aspartate aminotransferase-Lymphocyte Ratio Index (ALRI) were evaluated to assess a correlation with progression-free survival (PFS) and overall survival (OS). Results: In the overall population, PFS and OS were lower in patients with high SII (HR 1.64, p = 0.006 and HR 1.75, p = 0.004, respectively) and high ALRI (HR 2.13, p = 0.001 and HR 1.76, p = 0.02, respectively), but no difference was detected according to CII value. The multivariate analysis confirmed both SII and ALRI as independent prognostic factors for PFS (HR 1.64 and 2.82, respectively) and OS (HR 1.65 and 2.12, respectively). Conclusion: Our results demonstrate and confirm that IIs, and in particular SII and ALRI, are easy to measure prognostic markers for patient candidates to first line chemotherapy plus Bev for mCRC.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1758-8359Test

الوصول الحر: https://doaj.org/article/7c76b2cc5c08402fb671d3dfe99c2c81Test

المؤلفون: Francesco Giulio Sullo, Alessandro Passardi, Chiara Gallio, Chiara Molinari, Giorgia Marisi, Eleonora Pozzi, Leonardo Solaini, Alessandro Bittoni

المصدر: Journal of Clinical Medicine, Vol 13, Iss 9, p 2562 (2024)

مصطلحات موضوعية: rectal cancer, total neoadjuvant treatment, immune checkpoint inhibitors, nonoperative management, ctDNA, Medicine

الوصف: Rectal cancer presents a significant burden globally, often requiring multimodal therapy for locally advanced cases. Long-course chemoradiotherapy (LCRT) and short-course radiotherapy (SCRT) followed by surgery have been conventional neoadjuvant approaches. Recent trials favor LCRT due to improved local control. However, distant tumor recurrence remains a concern, prompting the exploration of total neoadjuvant therapy (TNT) as a comprehensive treatment strategy. Immune checkpoint inhibitors (ICIs) show promise, particularly in mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors, potentially revolutionizing neoadjuvant regimens. Nonoperative management (NOM) represents a viable alternative post-neoadjuvant therapy for selected patients achieving complete clinical response (cCR). Additionally, monitoring minimal residual disease (MRD) using circulating tumor DNA (ctDNA) emerges as a non-invasive method for the assessment of treatment response. This review synthesizes current evidence on TNT, ICIs, NOM, and ctDNA, elucidating their implications for rectal cancer management and highlighting avenues for future research and clinical application.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2077-0383/13/9/2562Test; https://doaj.org/toc/2077-0383Test

الوصول الحر: https://doaj.org/article/c1f3b2250642483881aabf33e85bec71Test

المؤلفون: Bittoni, Cecilia

الوصف: On April 11th, 2024, four events merged into this 2024 Ocean Decade Conference Satellite Event hosted by DCC-CR and co-hosted by CoastPredict Programme, Knowledge Hub on Sea Level Rise and Ocean and Climate Platform . This report summarises the results on engaging participants through polls and Q&A sessions to gather insights on coastal resilience, sea-level rise impacts, and international milestones for advancing resilience. Key outcomes included high engagement levels, with 110 out of 124 participants actively involved, and significant participation in polls. The event highlighted strategies for supporting coastal resilience, diverse interpretations of coastal resilience, and relevant sea-level rise-induced impacts. Additionally, anticipated international milestones and contributions to strengthening multi-hazard warning systems were discussed. The outcomes of the event align closely with the objectives of the Ocean Decade and Vision 2030 white paper 6, emphasising the importance of collaboration, ...

العلاقة: https://dx.doi.org/10.5281/zenodo.11203584Test

الإتاحة: https://doi.org/10.5281/zenodo.1120358310.5281/zenodo.11203584Test

المؤلفون: Baeten, Jared M, Palanee-Phillips, Thesla, Mgodi, Nyaradzo M, Mayo, Ashley J, Szydlo, Daniel W, Ramjee, Gita, Mirembe, Brenda Gati, Mhlanga, Felix, Hunidzarira, Portia, Mansoor, Leila E, Siva, Samantha, Govender, Vaneshree, Makanani, Bonus, Naidoo, Logashvari, Singh, Nishanta, Nair, Gonasagrie, Chinula, Lameck, Parikh, Urvi M, Mellors, John W, Balán, Iván C, Ngure, Kenneth, van der Straten, Ariane, Scheckter, Rachel, Garcia, Morgan, Peda, Melissa, Patterson, Karen, Livant, Edward, Bunge, Katherine, Singh, Devika, Jacobson, Cindy, Jiao, Yuqing, Hendrix, Craig W, Chirenje, Zvavahera M, Nakabiito, Clemensia, Taha, Taha E, Jones, Judith, Torjesen, Kristine, Nel, Annalene, Rosenberg, Zeda, Soto-Torres, Lydia E, Hillier, Sharon L, Brown, Elizabeth R, Aanyu, Dorothy, Abima, John, Abullarade, Janne, Agarwal, Priyanka, Ahluwalia, Surabhi, Akasiima, Simon Africa, Akello, Carolyne Agwau, Albert, Samuel, Alphale, Motsamai, Alphonse, Calins, Apeduno, Lucy, Aranda, Sara, Aridor, Orly, Arnolds, Shakeera, Asiimwe, Prossy, Atujuna, Millicent, Atwebembere, Didas, Baboolall, Lakshmi, Badana, Kiran, Balamusani, David, Banda, Gabriel, Banda, Towera Whitney, Baugh, Jennifer, Baziira, James Amos, Beamer, May, Bebeza, Sivuyisiwe Asanda, Bekker, Linda-Gail, Bell, Ian, Bemer, Meagan, Berman, Richard, Berthiaume, Jennifer, Bezak, Linda, Bhagwandin, Yashveer, Bhayat, Hassen Anwar, Bhengu, Nokulunga, Bhengu, Sonto, Bhoola, Aruna, Biira, Florence Asiimwe, Bittoni, Daniel, Black, Roberta, Blose, Nombuso Jacqueline, Boks, Pearl, Bolton, Stephen Gordon, Botya, Phathiswa, Brown, Amanda, Brown, Elizabeth, Brown, Helen, Bruce, Robyn Helen, Bukenya, Luke Erismus, Bukirwa, Aidah, Bunts, Lisa, Buthelezi, Fezile, Buthelezi, Mbongeleni William, Buthelezi, Samkelisiwe Dumisile, Byogero, Rose

المصدر: The Lancet HIV. 8(2)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Prevention, HIV/AIDS, Mental Health, Infectious Diseases, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Administration, Intravaginal, Adult, Anti-HIV Agents, Contraceptive Devices, Female, Female, HIV Infections, HIV-1, Humans, Malawi, Patient Compliance, Patient Safety, Pyrimidines, Seroconversion, South Africa, Tenofovir, Treatment Outcome, Uganda, Zimbabwe, MTN-025/HOPE Study Team, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences

الوصف: BackgroundTwo phase 3 clinical trials showed that use of a monthly vaginal ring containing 25 mg dapivirine was well tolerated and reduced HIV-1 incidence in women by approximately 30% compared with placebo. We aimed to evaluate use and safety of the dapivirine vaginal ring (DVR) in open-label settings with high background rates of HIV-1 infection, an important step for future implementation.MethodsWe did a phase 3B open-label extension trial of the DVR (MTN-025/HIV Open-label Prevention Extension [HOPE]). Women who were HIV-1-negative and had participated in the MTN-020/ASPIRE phase 3 trial were offered 12 months of access to the DVR at 14 clinical research centres in Malawi, South Africa, Uganda, and Zimbabwe. At each visit (monthly for 3 months, then once every 3 months), women chose whether or not to accept the offer of the ring. Used, returned rings were tested for residual amounts of dapivirine as a surrogate marker for adherence. HIV-1 serological testing was done at each visit. Dapivirine amounts in returned rings and HIV-1 incidence were compared with data from the ASPIRE trial, and safety was assessed. This study is registered with ClinicalTrials.gov, NCT02858037.FindingsBetween July 16, 2016, and Oct 10, 2018, of 1756 women assessed for eligibility, 1456 were enrolled and participated in the study. Median age was 31 years (IQR 27-37). At baseline, 1342 (92·2%) women chose to take the DVR; ring acceptance was more than 79% at each visit up until 12 months and 936 (73·2%) of 1279 chose to take the ring at all visits. 12 530 (89·3%) of 14 034 returned rings had residual dapivirine amounts consistent with some use during the previous month (>0·9 mg released) and the mean dapivirine amount released was greater than in the ASPIRE trial (by 0·21 mg; p

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/65d0c7r9Test

المؤلفون: Raimondi, A., Morano, F., Trarbach, T., Karthaus, M., Lonardi, S., Fruehauf, S., Cremolini, C., Graeven, U., Bittoni, A., Mueller, L., Bianchi, A. Sartore, Aranda, E., Boige, V., Stintzing, S., Di Bartolomeo, M., Koenig, A., Pietrantonio, F., Modest, D.

المساهمون: Raimondi, A. Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy, Morano, F. Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy, Pietrantonio, F. Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy, Trarbach, T. Univ Hosp Essen, Rehazentrum Meer, Bad Zwischenahn, Essen, Germany, Trarbach, T. Univ Hosp Essen, Dept Med Oncol, West German Canc Ctr, Westdeutsches Turmozentrum, Essen, Germany, Lonardi, S. Munich Hosp Neuperlach, Dept Hematol & Oncol, Munich, Germany, Fruehauf, S. Veneto Inst Oncol IRCCS, Med Oncol, Padua, Italy, Cremolini, C. Dr Hancken Hosp, Stade, Germany, Graeven, U. Univ Pisa, Azienda Osped Univ Pisana, Med Oncol Unit, Dept Translat Res & New Technol Med & Surg, Pisa, Italy, Bittoni, A. Kliniken Maria Hilf GmbH, Monchengladbach, Germany, Bittoni, A. IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Med Oncol & Hematol Unit, Rozzano, Italy, Mueller, L. Oncol Practice Unter Ems, Leer, Germany, Bianchi, A. Sartore Univ Milan, Div Oncol, Grande Osped Metropolitano Niguarda, Milan, Italy, Bianchi, A. Sartore Univ Milan, Dept Oncol & Hematol, Milan, Italy, Boige, V. Univ Cordoba, Inst Maimonides Invest Biomed Cordoba, CIBERONC, Hosp Univ Reina Sofia,Inst Salud Carlos 3, Cordoba, Spain, Stintzing, S. Gustave Roussy, Villejuif, France, Stintzing, S. Charite Univ med Berlin, Dept Hematol Oncol & Tumorimmunol, Berlin, Germany, Stintzing, S. Free Univ Berlin, Berlin, Germany, Stintzing, S. Humboldt Univ, Berlin, Germany, Berlin Inst Hlth, Berlin, Germany, Di Bartolomeo, M. Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy, Pietrantonio, F. Univ Med Gottingen, Dept Gastroenterol, Gottingen, Germany, Amgen

العلاقة: http://hdl.handle.net/10668/21914Test; http://www.annalsofoncology.org/article/S0923753422011103/pdfTest; 823826500341

الإتاحة: https://doi.org/10.1016/j.annonc.2022.04.420Test
http://hdl.handle.net/10668/21914Test
http://www.annalsofoncology.org/article/S0923753422011103/pdfTest

المؤلفون: Orsi, Giulia, Cavaliere, Alessandro, Tortora, Giampaolo, Lonardi, Sara, Macchini, Marina, Di Marco, Mariacristina, Giordano, Guido, Vasile, Enrico, Scartozzi, Mario, Bozzarelli, Silvia, Noventa, Silvia, Rodriquenz, Maria Grazia, Militello, Anna Maria, Rapposelli, Ilario Giovanni, Garajova, Ingrid, De Lorenzo, Stefania, Merelli, Barbara, Bittoni, Alessandro, Salvatore, Lisa, Procaccio, Letizia, Paratore, Chiara, Spallanzani, Andrea, Peretti, Umberto, Niger, Monica, Giommoni, Elisa, Bernardini, Ilaria, Tamburini, Emiliano, Bernardino, Katia, Forti, Laura, Valente, Maria Maddalena, Cascinu, Stefano, Milella, Michele, Reni, Michele

المساهمون: Orsi, Giulia, Cavaliere, Alessandro, Tortora, Giampaolo, Lonardi, Sara, Macchini, Marina, Di Marco, Mariacristina, Giordano, Guido, Vasile, Enrico, Scartozzi, Mario, Bozzarelli, Silvia, Noventa, Silvia, Rodriquenz, Maria Grazia, Militello, Anna Maria, Rapposelli, Ilario Giovanni, Garajova, Ingrid, De Lorenzo, Stefania, Merelli, Barbara, Bittoni, Alessandro, Salvatore, Lisa, Procaccio, Letizia, Paratore, Chiara, Spallanzani, Andrea, Peretti, Umberto, Niger, Monica, Giommoni, Elisa, Bernardini, Ilaria, Tamburini, Emiliano, Bernardino, Katia, Forti, Laura, Valente, Maria Maddalena, Cascinu, Stefano, Milella, Michele, Reni, Michele

مصطلحات موضوعية: Pancreatic cancer

الوصف: Background: Pancreatic ductal adenocarcinoma (PDAC) harbouring germline BRCA1-2 pathogenic variants (gBRCA1-2pv) is a distinct nosological entity. Information on second-line therapy (2LT) outcome in this setting is lacking. Methods: Data of gBRCA1-2pv metastatic PDAC patients treated with chemotherapy were collected. A primary analysis of 2LT RECIST response, median progression-free survival (mPFS2) and overall survival (mOS2), was performed. A secondary analysis addressed the impact of timing of platinum introduction on the outcome of patients receiving at least a first-line combination chemotherapy (1LT). Results: Eighty-four gBRCA1-2pv metastatic PDAC patients were enrolled. The primary analysis, including 43 patients, highlighted a significant improvement of mPFS2 and a doubled response rate, in the platinum-based 2LT subgroup as compared to the platinum-free (8.8 versus 3.7 months, p = 0.013). Seventy-seven patients were included in the secondary analysis. Median PFS1 of 3- and 4-drug platinum-based 1LT significantly outperformed both platinum-free combinations and platinum-based doublets (11.4 versus 6.4 versus 7.9 months, p = 0.01). Albeit still immature, data on mOS paralleled those on mPFS. Conclusions: This study highlighted the beneficial role of platinum agents in gBRCA1-2pv PDAC patients also in second-line treatment setting. However, our data suggest that early use of 3- and 4-drug platinum-based chemotherapy combinations provides a survival outcome advantage.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36482190; info:eu-repo/semantics/altIdentifier/wos/WOS:000901534800003; volume:128; issue:5; firstpage:877; lastpage:885; numberofpages:9; journal:BRITISH JOURNAL OF CANCER; https://hdl.handle.net/11584/356508Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85143587842; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977912Test/

الإتاحة: https://doi.org/10.1038/s41416-022-02086-wTest
https://hdl.handle.net/11584/356508Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977912Test/

المؤلفون: Alessandro Passardi, Alessandro Bittoni, Zhigang Bai, Zhongtao Zhang, Cornelis Sier, Yulong He, Endrit Shahini, Antonio Giovanni Solimando

المصدر: Frontiers in Oncology, Vol 13 (2023)

مصطلحات موضوعية: angiogenesis, gastrointestinal cancer, ramucirumab, anti-angiogenic therapies, apatinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2023.1147849/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/ac659dba3c0a48f483b574cf60cd000fTest